A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers - Raison, CL; Rutherford, RE; Woolwine, BJ (JAMA psychiatry, 2013)
doi:10.1001/2013.jamapsychiatry.4